The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with Bortezomib

Cancer Research

Volumn 69, Issue 10, 2009, Pages 4415-4423

  Milani, Manuela ^a   Rzymski, Tomasz ^a   Mellor, Howard R ^a   Pike, Luke ^a   Bottini, Alberto ^b   Generali, Daniele ^b   Harris, Adrian L ^a,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b Breast Unit   (Italy)

^c IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; BORTEZOMIB; HISTONE DEACETYLASE 6; LC3B PROTEIN; PROTEASOME; PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; AUTOPHAGY; BREAST CANCER; CANCER CELL; CELL DEATH; CELL PROTECTION; CONTROLLED STUDY; DRUG MECHANISM; ENDOPLASMIC RETICULUM STRESS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; UPREGULATION;

ACTIVATING TRANSCRIPTION FACTOR 4; ANTINEOPLASTIC AGENTS; AUTOPHAGY; BORONIC ACIDS; BREAST NEOPLASMS; CELL DIVISION; CELL LINE, TUMOR; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM PROTEINS; POLYMERASE CHAIN REACTION; PYRAZINES; RNA, NEOPLASM; RNA, SMALL INTERFERING;

EID: 66249085237     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-2839     Document Type: Article

References (38)

1. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-2622 (Pubitemid 29269108)
2. Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 2004;5:417-421 (Pubitemid 38610244)
3. Caravita T, de Fabritiis P, Palumbo A, Amadori S, Boccadoro M. Bortezomib: efficacy comparisons in solid tumors and hematologic malignancies. Nat Clin Pract Oncol 2006;3:374-387 (Pubitemid 44027292)
4. Nawrocki ST, Carew JS, Pino MS, et al. Bortezomib sensitizes pancreatic cancer cells to endoplasmic reticulum stress-mediated apoptosis. Cancer Res 2005;65:11658-11666 (Pubitemid 41821726)
5. Rzymski T, Harris AL. The unfolded protein response and integrated stress response to anoxia. Clin Cancer Res 2007;13:2537-2540 (Pubitemid 46788018)
6. Harding HP, Zhang Y, Ron D. Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature 1999;397:271-274 (Pubitemid 29051178)
7. Yorimitsu T, Klionsky DJ. Endoplasmic reticulum stress: a new pathway to induce autophagy. Autophagy 2007;3:160-162 (Pubitemid 46449112)
8. Yorimitsu T, Nair U, Yang Z, Klionsky DJ. Endoplasmic reticulum stress triggers autophagy. J Biol Chem 2006;281:30299-30304 (Pubitemid 44537037)
9. Talloczy Z, Jiang W, Virgin HWt, et al. Regulation of starvation- and virus-induced autophagy by the eIF2α kinase signaling pathway. Proc Natl Acad Sci U S A 2002;99:190-195 (Pubitemid 34060339)
10. Kouroku Y, Fujita E, Tanida I, et al. ER stress (PERK/eIF2α phosphorylation) mediates the polyglutamine-induced LC3 conversion, an essential step for autophagy formation. Cell Death Differ 2007;14:230-239 (Pubitemid 46092226)
11. Shimizu S, Kanaseki T, Mizushima N, et al. Role of Bcl-2 family proteins in a non-apoptotic programmed cell death dependent on autophagy genes. Nat Cell Biol 2004;6:1221-1228 (Pubitemid 39625121)
12. Shintani T, Klionsky DJ. Autophagy in health and disease: a double-edged sword. Science 2004;306:990-995 (Pubitemid 39482894)
13. Shao Y, Gao Z, Marks PA, Jiang X. Apoptotic and autophagic cell death induced by histone deacetylase inhibitors. Proc Natl Acad Sci U S A 2004;101:18030-18035 (Pubitemid 40054069)
14. Haggarty SJ, Koeller KM, Wong JC, Grozinger CM, Schreiber SL. Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. Proc Natl Acad Sci U S A 2003;100:4389-4394 (Pubitemid 36457739)
15. Rodriguez-Gonzalez A, Lin T, Ikeda AK, Simms-Waldrip T, Fu C, Sakamoto KM. Role of the aggresome pathway in cancer: targeting histone deacetylase 6-dependent protein degradation. Cancer Res 2008;68:2557-2560
16. Rzymski T, Paantjens A, Bod J, Harris AL. Multiple pathways are involvedin the anoxia response of SKIP3 including HuR-regulated RNA stability, NF-κB and ATF4. Oncogene 2008;27:4532-4543
17. Birle DC, Hedley DW. Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors. Cancer Res 2007;67:1735-1743 (Pubitemid 46383400)
18. Shin DH, Chun YS, Lee DS, Huang LE, Park JW. Bortezomib inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated repression of hypoxia-inducible factor-1. Blood 2008;111:3131-3136
19. Giatromanolaki A, Koukourakis MI, Pezzella F, et al. Expression of prolyl-hydroxylases PHD-1, 2 and 3 and of the asparagine hydroxylase FIH in non-small cell lung cancer relates to an activated HIF pathway. Cancer Lett 2008;262:87-93.
20. Engel RH, Brown JA, Von Roenn JH, et al. A phase II study of single agent bortezomib in patients with metastatic breast cancer: a single institution experience. Cancer Invest 2007;25:733-737 (Pubitemid 350223168)
21. Yang CH, Gonzalez-Angulo AM, Reuben JM, et al. Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits. Ann Oncol 2006;17:813-817
22. Codony-Servat J, Tapia MA, Bosch M, et al. Differential cellular and molecular effects of bortezomib, a proteasome inhibitor, in human breast cancer cells. Mol Cancer Ther 2006;5:665-675
23. Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci U S A 2003;100:9946-9951 (Pubitemid 37087048)
24. Bi M, Naczki C, Koritzinsky M, et al. ER stress-regulated translation increases tolerance to extreme hypoxia and promotes tumor growth. EMBO J 2005;24:3470-3481 (Pubitemid 41486784)
25. Obeng EA, Carlson LM, Gutman DM, Harrington WJ, Jr., Lee KP, Boise LH. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 2006;107:4907-916
26. Nawrocki ST, Carew JS, Dunner K, Jr., et al. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res 2005;65:11510-11519 (Pubitemid 41821709)
27. Harding HP, Zhang Y, Zeng H, et al. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell 2003;11:619-633 (Pubitemid 36385118)
28. Blais JD, Filipenko V, Bi M, et al. Activating transcription factor 4 is translationally regulated by hypoxic stress. Mol Cell Biol 2004;24:7469-7482 (Pubitemid 39121475)
29. Fribley A, Zeng Q, Wang CY. Proteasome inhibitor PS-341 induces apoptosis through induction of endoplasmic reticulum stress-reactive oxygen species in head and neck squamous cell carcinoma cells. Mol Cell Biol 2004;24:9695-9704 (Pubitemid 39458799)
30. Jiang HY, Wek RC. Phosphorylation of the α-subunit of the eukaryotic initiation factor-2 (eIF2α) reduces protein synthesis and enhances apoptosis in response to proteasome inhibition. J Biol Chem 2005;280:14189-14202 (Pubitemid 40517321)
31. Kim R, Emi M, Tanabe K, Murakami S. Role of the unfolded protein response in cell death. Apoptosis 2006;11:5-13. (Pubitemid 43151639)
32. Fels DR, Ye J, Segan AT, et al. Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways. Cancer Res 2008;68:9323-9330
33. Amaravadi RK, Thompson CB. The roles of therapy-induced autophagy and necrosis in cancer treatment. Clin Cancer Res 2007;13:7271-7279
34. Reddy RK, Mao C, Baumeister P, Austin RC, Kaufman RJ, Lee AS. Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis induced by topoisomerase inhibitors: role of ATP binding site in suppression of caspase-7 activation. J Biol Chem 2003;278:20915-20924 (Pubitemid 36806399)
35. Tanabe M, Izumi H, Ise T, et al. Activating transcription factor 4 increases the cisplatin resistance of human cancer cell lines. Cancer Res 2003;63:8592-8595 (Pubitemid 38064031)
36. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002;62:3387-3394 (Pubitemid 34651384)
37. Boyault C, Sadoul K, Pabion M, Khochbin S. HDAC6, at the crossroads between cytoskeleton and cell signaling by acetylation and ubiquitination. Oncogene 2007;26:5468-5476
38. Bazzaro M, Lin Z, Santillan A, et al. Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib anda novel HDAC6 inhibitor. Clin Cancer Res 2008;14:7340-7347